Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B
Open Access
- 1 December 2004
- journal article
- clinical trial
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 99 (8) , 865-871
Abstract
The immunogenicity and safety of a new recombinant hepatitis B vaccine from the Instituto Butantan (Butang) were evaluated in a multicenter, double-blind, prospective equivalence study in three centers in Brazil. Engerix B was the standard vaccine. A total of 3937 subjects were recruited and 2754 (70%) met all protocol criteria at the end of the study. All the subjects were considered healthy and denied having received hepatitis B vaccine before the study. Study subjects who adhered to the protocol were newborn infants (566), children 1 to 10 years old (484), adolescents from 11 to 19 years (740), adults from 20 to 30 years (568), and adults from 31 to 40 years (396). Vaccine was administered in three doses on the schedule 0, 1, and 6 months (newborn infants, adolescents, and adults) or 0, 1, and 7 months (children). Vaccine dose was intramuscular 10 microg (infants, children, and adolescents) or 20 microg (adults). Percent seroprotection (assumed when anti-HBs titers were > 10 mIU/ml) and geometric mean titer (mIU/ml) were: newborn infants, 93.7% and 351.1 (Butang) and 97.5% and 1530.6 (Engerix B); children, 100% and 3600.0 (Butang) and 97.7% and 2753.1 (Engerix B); adolescents, 95.1% and 746.3 (Butang) and 96% and 1284.3 (Engerix B); adults 20-30 years old, 91.8% and 453.5 (Butang) and 95.5% and 1369.0 (Engerix B); and adults 31-40 years old, 79.8% and 122.7 (Butang) and 92.4% and 686.2 (Engerix B). There were no severe adverse events following either vaccine. The study concluded that Butang was equivalent to Engerix B in children, and less immunogenic but acceptable for use in newborn infants, adolescents, and young adults.Keywords
This publication has 15 references indexed in Scilit:
- Immunogenicity of three recombinant hepatitis B vaccines administered to students in three doses containing half the antigen amount routinely used for adult vaccinationRevista do Instituto de Medicina Tropical de São Paulo, 2004
- The Effect of Age on Immunologic Response to Recombinant Hepatitis B Vaccine: A Meta‐analysisClinical Infectious Diseases, 2002
- Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 yearsVaccine, 2002
- Over a decade of experience with a yeast recombinant hepatitis B vaccineVaccine, 1999
- Safety and immunogenicity of hepatitis B vaccine ButaNG in adultsRevista do Instituto de Medicina Tropical de São Paulo, 1999
- PRELIMINARY REPORT OF THE USE ON ADULTS OF A RECOMBINANT YEAST-DERIVED HEPATITIS B VACCINE MANUFACTURED BY INSTITUTO BUTANTANRevista do Instituto de Medicina Tropical de São Paulo, 1997
- Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studiesThe Pediatric Infectious Disease Journal, 1993
- Immunization aganist hepatitis B in children from endemic zone: evaluation of the antibody response against the DNA recombinant vaccine (Engerix B-20 mcg)Revista do Instituto de Medicina Tropical de São Paulo, 1993
- Summary of safety and efficacy data on a yeast-derived hepatitis B vaccineThe American Journal of Medicine, 1989
- Classification and Evaluation of the ObesitiesMedical Clinics of North America, 1989